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Abstract
Background: Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease in which increased apoptosis and
decreased apoptotic cells removal has been described as most relevant in the pathogenesis. Long-chain acyl-coenzyme A
synthetases (ACSLs) have been involved in the immunological dysfunction of mouse models of lupus-like autoimmunity and
apoptosis in different in vitro cell systems. The aim of this work was to assess among the ACSL isoforms the involvement of
ACSL2, ACSL4 and ACSL5 in SLE pathogenesis.
Findings:With this end, we determined the ACSL2, ACSL4 and ACSL5 transcript levels in peripheral blood mononuclear cells
(PBMCs) of 45 SLE patients and 49 healthy controls by quantitative real time-PCR (q-PCR). We found that patients with SLE
had higher ACSL5 transcript levels than healthy controls [median (range), healthy controls = 16.5 (12.3–18.0) vs. SLE = 26.5
(17.8–41.7), P = 3.9610 E-5] but no differences were found for ACSL2 and ACSL4. In in vitro experiments, ACSL5 mRNA
expression was greatly increased when inducing apoptosis in Jurkat T cells and PBMCs by Phorbol-Myristate-Acetate plus
Ionomycin (PMA+Io). On the other hand, short interference RNA (siRNA)-mediated silencing of ACSL5 decreased induced
apoptosis in Jurkat T cells up to the control levels as well as decreased mRNA expression of FAS, FASLG and TNF.
Conclusions: These findings indicate that ACSL5 may play a role in the apoptosis that takes place in SLE. Our results point to
ACSL5 as a potential novel functional marker of pathogenesis and a possible therapeutic target in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is a complex genetic
autoimmune disorder which predominantly affects women and
leads to the production of antibodies against an individual’s own
healthy tissues, aberrant formation of immune complexes (IC), and
inflammation of multiple organs. As a consequence skin rashes,
joint pain, anaemia, cardiovascular-atherosclerosis and renal
diseases are the principal clinical manifestations. While no known
cure for SLE exists, current treatments that range from
antimalarials to corticosteroids and immunosuppressive agents
have markedly reduced short-term mortality rates. Long-term
mortality rates, on the other hand, are increasingly influenced by
cardiovascular complications [1].
Accelerated apoptosis of circulating lymphocytes and/or
impaired clearance of apoptotic cells are already known to be a
hallmark of SLE [2]. Impaired engulfment of early apoptotic cells
may cause secondary necrosis and release of intracellular
autoantigens, and then trigger autoimmune reactions in SLE
[3,4]. The dysfunction of apoptosis may be a direct consequence of
alterations in proteins/genes such as Fas, FasL, Bcl-2 and C1q
among others [5,6].
Human long-chain acyl-CoA synthetases (ACSL, EC6.2.1.3)
activate fatty acids with chain lengths from 12 to 20 carbon atoms
by esterification with coenzyme A (CoA). The acyl-CoAs formed
are essential for complex lipid synthesis, protein modification,
beta-oxidation, regulation of various physiological processes and
remodelling of membranes [7]. ACSLs differ in fatty acid types
and tissue expression preference. ACSL5 has a substrate
preference for C16-C18 unsaturated fatty acids and is expressed
in small intestine, as well as in lungs, liver and other tissues,
localizing at the outer mitochondrial membrane and microsomes
[8,9].
Acyl-coAs are lipid metabolic intermediates that have been
associated to metabolism regulation systems and gene expression
[10]. Besides, acyl-coAs have long been associated to apoptosis,
mostly because of their effect on membrane stability, signaling
pathways and secondary metabolite activity [11–13].
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Although the contribution of lipid metabolic pathways to
autoimmunity, and specifically to SLE, is poorly understood,
several in vivo and in vitro evidences indicate that ACSLs may play
an important role in the immune dysfunction of lupus-like mouse
models [14,15]. In addition, autoimmunity and inflammation are
associated with marked changes in lipid and lipoprotein
metabolism in SLE [16,17]. ACSL5, on the contrary, has been
associated with cell development and maturation, physiopatho-
logical processes, apoptosis and tumorigenesis [18–21].
In spite of these suggestive precedents, this study is the first to
approach a possible involvement of ACSL5 in autoimmune
diseases and specifically in SLE. We hypothesized an implication
of ACSL5 in the pathogenesis of SLE, which is associated with the
increased apoptosis seen in the disease, since this gene has already
been associated to apoptosis in other tissues and diseases. For that,
we investigated the ACSL5 transcripts levels in peripheral blood
mononuclear cells (PBMCs) from SLE patients and healthy donors
to seek for significant differences. Moreover, we focused on
whether ACSL5 transcript levels were related to activation-
induced cell death (AICD) in Jurkat T cells and PBMCs as models
already described [22], and discuss its potential association with
apoptosis found in SLE. Our results indicated that ACSL5
transcript levels were higher in SLE than in controls and that
silencing ACSL5 mRNA by short interference RNA (siRNA)
decreased the apoptosis induced by phorbol-myristate-acetate plus
ionomycin (PMA+Io)-activation of Jurkat T cells, thus implicating
ACSL5 in AICD.
Results
ACSLs measurements in patients and controls
The aim of this study was to investigate the mRNA expression
levels of ACSL5 in PBMCs from SLE patients and control subjects
by means of qPCR. The main characteristics of the SLE patients
and controls relevant for this study are listed in Table 1. We have
quantified mRNA levels in two conditions. Firstly, from freshly
extracted and non-activated PBMCs named as ACSL5(N),
potentially indicative of physiological status of each group, either
patients or controls. The second type of measurement for ACSL5
was done after 24 h of in vitro stimulation with PMA+Io named
ACSL5(A). This kind of activation may resemble to a natural
polyclonal activation conditioned by the pathological status of the
individuals from whom PBMCs were extracted and may be
indicative of the maximum response potential of PBMCs. Finally,
a parameter that we set up to equilibrate differences owning to
undetermined factors between measurements (supposing to affect
similarly to the untreated and activated cultures), was the
stimulation index (SI), that is, the ratio between ACSL5(A) and
ACSL5(N) expression levels [23].
ACSL5 in SLE patients vs. healthy controls
As shown in Figure 1A, comparing with healthy subjects, freshly
collected PBMCs from SLE patients had higher expression levels
of mRNA for ACSL5 than controls [median (range); CTL = 16.5
(12.3–18) vs. SLE = 26.5 (17.8–41.7), P = 3.961025]. No signifi-
cant difference was found for ACSL2 and ACSL4 between healthy
controls and SLE patients (unpublished data). In activated
PBMCs, there were no differences between expression levels from
SLE patients and controls. ACSL5(SI) was significantly lower in
SLE patients than in controls (median (range); CTL = 5.1 (2.5–6.8)
vs. SLE = 1.9 (1.2–3.4), P = 1.861025), suggesting an enhanced
transcription of ACSL5 in SLE patients that was close to
maximum state of provoked activation.
ACSL5 difference between male and female healthy
controls
While SLE group had similar age to the healthy control group,
the male to female ratio was clearly different, so we took this last
characteristic into account and presented experiments to deter-
mine gender influence into ACSL5 transcript levels. As shown in
Figure 1B, ACSL5(N), (A) and (SI) values were similar in male and
female groups of healthy controls, therefore it was deduced that
gender was not associated with differences of ACSL5 transcript
levels and hence we could establish that there were no differences
between SLE patients and controls.
ACSL5 differences between prednisone treated and
untreated SLE patients
Another important consideration to discard confounder factors
was the effect of drug treatments in the ACSL5 mRNA levels.
Amongst the several drug-treatments of SLE patients indicated in
Table 1, only the corticosteroid prednisone affected ACSL5
mRNA levels. Comparing transcript level differences between
these two groups of SLE patients, we found a lower ACSL5(N)
transcript levels in treated than untreated group as shown in
Figure 1C. These results point to an even higher ACSL5 transcript
levels associated with pathology if patients were not treated with
Table 1. Main characteristics of study subjects with systemic
lupus erythematosus.
General Characterisitics Patients (n = 45)
Age (yrs)1 42613
Female (%)2 88
SLE characteristics
Disease duration (yrs) 13.368.6
Age at SLE diagnosis (yrs) 31.6613.1
SLE complications
Arthrites (%) 90
Renal involvement (%) 28
Serositis (%) 23
Haematological manifestations (%) 33
Neurological manifestations (%) 23
Positive anti-dsDNA (ever) (%) 83
Antiphospholipid antibody (ever) (%) 28
Activity
SLEDAI score 4.463.6
SDI score 1.2361.46
Treatments
Current use of prednisone (%)3 68
Current use of HCQ (%) 74
Mean current prednisone dose (mg/day) 3.663.1
Mean current HCQ dose (mg/day) 91659
Immunosuppressant agents (%) 33
1Age of Control group: n = 49, mean 6 SD= 36.91 614 (19–61). No significant
difference with SLE group (P-value. 0.05).
2Female percentage of control group: 50%. No difference of ACSL5 levels
between male and females of control group (see Figure 1B).
3Prednisone treatment to patients affected ACSL5 transcript levels (see
Figure 1C).
doi:10.1371/journal.pone.0028591.t001
ACSL5 in SLE and Apoptosis in Lymphocytes
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prednisone which would follow our previous results referring to
higher ACSL5 expression in SLE patients than in healthy controls.
ACSL effect in SLE and as diagnostic marker
To determine the effect on SLE (odds ratio, OR), logistic
regression analysis was performed showing the beta coefficient and
odds ratio with 95% confidence intervals (Table 2). ACSL5 (SI)
had an OR of 0.68 (95% CI = 0.54420.854) for each increasing
unit variation. Analysis of the ROC curves for ACSL5 from
PBMCs showed that the AUC was highest for ACSL5 (SI) (AUC
= 0.776) as indicated in Table 2, which reflected a potential utility
in diagnosis.
Effect of PMA+Io activation in PBMCs
We obtained PBMCs from two controls and cultured them with
or without PMA+Io up to 24 h followed by PI alone or Annexin V/
PI double staining as described in material and methods (Figure 2
A–B). Results showed more than 50% of PI incorporation after 24 h
of activation with PMA+Io compared to controls (P = 0.0289).
Annexin V/PI double staining showed no significant differences
compared to controls due to an abnormally elevated apoptosis in
controls. We analyzed then mRNA expression of several relevant
genes associated with apoptosis to partly determine the effect of
PMA+Io in the apoptotic pathway (Figure 2 D–I). BCL-2 showed a
4-fold decrease, while FAS, FASLG, TRAIL (TNFSF10), TNF and
CASP3 increased by 3-, 5-, 2-, 3- and 2-fold respectively, thus
corroborating and induction of AICD in PBMCs by PMA+Io
activation.
Figure 1. Association of ACSL5 mRNA expression levels with SLE. A) ACSL5 transcript levels in PBMCs from healthy controls (0) and SLE
patients (1) for ACSL5(N) (number of samples n: 0 = 49, 1 = 45), activated ACSL5(A) (n, 0 = 34, 1 = 40) and the ratio A/N (ACSL5(SI) (n, 0 = 34, 1 = 40). B)
ACSL5 transcript levels in PBMCs from males (0) (n = 24) and females (1) (n = 25), all of them from the control group. C) ACSL5 transcript levels in
PBMCs from prednisone treated (1) (n = 28) and untreated (0) (n = 12) SLE patients. Results are represented in box plots given medians, quartiles,
outsiders (circle points) and extremes (asterisk points). P-values of differences between the groups (0) and (1) are defined by Mann-Whitney Statistics.
N.S. stands for non significant.
doi:10.1371/journal.pone.0028591.g001
Table 2. Logistic regression analysis to determine the effect
on diseases and the area under curve (AUC) of ACSL5 values
in PBMCs.
ACSL5 Coefficient Wald P-value OR, 95% CI AUC
ACSL5(N) 0.047 7.26 0.007 1.048 (1.013–1.084) 0.732
ACSL5(A) 20.011 5.316 0.021 0.989 (0.980–0.998) 0.598
ACSL5(SI) 0.384 11.138 0.001 0.681 (0.544–0.854) 0.776
Results are represented with the beta coefficient and the odds ratios (OR) with
95% confidence intervals (CI).
doi:10.1371/journal.pone.0028591.t002
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On the other hand, ACSL5 mRNA levels increased in a time-
dependent course when activated with PMA+Io (mean6SD;
24 h = 5.5160.41 vs. CTL = 1.0260.13; P = 0.0049) (Figure 2C),
thus correlating with the expression of pro-apoptosis genes and the
induction of apoptosis in PBMCs.
Effect of PMA+Io activation on AICD in Jurkat T cells
Jurkat T cells were activated with PMA+Io for up to 24 h,
followed by PI alone or Annexin V/PI double staining
(Figure 3A–B). PI positive cells in PMA+Io-activated Jurkat
cells increased to 20, 27 and 40% at 2, 6 and 24 h respectively,
whereas it was 8% in untreated control cells. On the other hand,
Annexin V positive cells increased 2 and 23% at 2 and 24 h,
respectively, compared with controls (P = 0.0256). These results
agree with several studies describing PMA+Io-induced AICD in
lymphocytes [22]. On the other hand, Annexin V positive cells
increased, compared to controls, 2 and 23% at 2 and 24 h,
respectively. We analyzed, as with PBMCs, mRNA expression
of several relevant genes associated to apoptosis to partly
determine the effect of PMA+Io in the apoptotic pathway
(Figure 3 D–I). FASLG, TNF and TRAIL (TNFSF10) were
induced 14, 8 and 3 times respectively, thus agreeing with
cytometry results.
Effect of PMA+Io activation in ACSL5 mRNA expression
Jurkat T cells activated with PMA+Io showed an increased level
of ACSL5 mRNA – time dependent – by approximately 5-fold at
24 h compared to untreated control cells (mean6SD; PMA+Io =
0.3660.04 vs. CTL = 0.07960.002; P = 0.018) (Figure 3C), so
indicating that ACSL5 is inducible by PMA+Io in Jurkat T cells.
Here we concluded that the increased ACSL5 transcript levels
correlated with PMA+Io-induced apoptosis in Jurkat cells.
Effect of ACSL5 transcript levels in PMA+Io-inducing
apoptosis
We used short interference RNA (siRNA) technology to silence
ACSL5 gene expression to test whether it was implicated in AICD in
Jurkat T cells. For that purpose siACSL5 and a transfection control
(siRNA) were introduced by electroporation into Jurkat T cells,
Figure 2. Effect of PMA+Io activation in PBMCs. PBMCs from healthy controls were obtained and cultured in the presence or absence of
PMA+Io for up to 24 h. A) Cells were collected at defined times, washed with PBS, fixed with 70% Ethanol, stained with Propidium Iodide (PI) and
analyzed in a FACSCaliburTM flow cytometer to determine the apoptotic hipodiploid cell fragments (defined as percentage of PI incorporation). B)
Cells were washed twice with PBS and double stained with Annexin V and PI, then analyzed by FACS to determine the percentage of apoptotic cells
(Annexin V positive and double positive cells). C–I) Total RNA was extracted, cDNA synthesized and qRT-PCR implemented to determine mRNA
expression. Results are given by means of three independent experiments and the bars show the standard deviation. P-value has been calculated
with the paired Student t test.
doi:10.1371/journal.pone.0028591.g002
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obtaining 80% silencing approximately after 18 h of transfection
(Figure 4A). Silencing was particularly important in PMA+Io-
activated cells (mean6SD; siACSL5 = 0.03460.0005 vs. siRNA =
0.1960.08; P = 0.038) due to a low expression level of ACSL5 in
untreated cells but high expression following PMA+Io activation.
We then proceeded to test ACSL5 implication in PMA+Io-
induced apoptosis in Jurkat T cells by FACS (Figure 4 B–C).
Following PI alone or Annexin V/PI double staining, analysis of
transfected Jurkat samples showed a 35% decrease approximately
in both experiments – lowering to control levels – in siACSL5
compared to siRNA transfected Jurkat T cells when they were
activated with PMA+Io (mean6SD; PI Incorporation: siACSL5 =
4767 vs. siRNA = 7566; P = 0.0246. Annexin V positive cells:
siACSL5 = 4769 vs. siRNA = 7262; P = 0.0242). It is important
to note that there was an elevated apoptosis in controls – and
possibly in stimulated too – due to the necessity to stimulate cells
with PMA+Io right after transfection because of short life of
siRNAs, and so the impossibility to eliminate dead cells from the
nucleofection process.
Following prior experiments we analyzed mRNA expression of
several apoptotic genes, finding that FAS, FASLG and TNF
decreased 1.3-, 2.6- and 1.6-fold in siACSL5-transfected cells
compared to controls after stimulation with PMA+Io. These
findings imply a direct role of ACSL5 in PMA+Io-induced
apoptosis in Jurkat cells.
Discussion
The aim of this study was to investigate the role of ACSL5 in
SLE pathogenesis. We found that ACSL5 transcript level was
significantly increased in PBMCs from SLE patients compared to
controls. This association was not influenced by the different
female/male ratio of the cohorts since they did not show ACSL5
differences. The stimulation index (SI), which equilibrates
undetermined individual differences, showed a significantly greater
stimulation increase in PBMCs from controls compared to SLE
patients. Taken that SLE patients present a persistent state of
activation of lymphocytes with oversecretion of pro-inflammatory
cytokines [24], we could suggest that ACSL5 mRNA was
overexpressed in SLE patients as a consequence of this chronic
activated state of cells and thus exert a role in lymphocyte
activation. Unfortunately, we could not establish a relationship
Figure 3. Effect of PMA+Io activation in Jurkat T cells. Jurkat T cells were cultured in the presence or absence of PMA+Io for up to 24 h. A) Cells
were collected at defined times, washed with PBS, fixed with 70% Ethanol, stained with Propidium Iodide (PI) and analyzed in a FACSCaliburTM flow
cytometer to determine the apoptotic hipodiploid cell fragments (defined as percentage of PI incorporation). B) Cells were washed twice with PBS
and double stained with Annexin V and PI, then analyzed by FACS to determine the percentage of apoptotic cells (Annexin V positive and double
positive cells). C–I) Total RNA was extracted, cDNA synthesized and qRT-PCR implemented to determine mRNA expression. Results are given by
means of three independent experiments and the bars show the standard deviation. P-value has been calculated with the paired Student t test.
doi:10.1371/journal.pone.0028591.g003
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between ACSL5 and cytokine expression in hematopoietic cell
lines (unpublished data). In this way, a higher degree of apoptosis
in T-lymphocytes in SLE patients has been found to be directly
correlated with disease activity [4]. In addition, we observed that
corticosteroids, used to reduce disease activity and systemic
inflammation in SLE, decreased ACSL5 transcript levels,
suggesting a strength link between inflammation (disease activity),
apoptosis and ACSL5 levels.
There is little information about ACSL expression in PBMCs
and diseases. One interesting evidence come from a microarray
gene expression study of about 10,000 genes in PBMCs from 7
rheumatoid arthritis (RA) patients with rheumatoid factor (RF), 6
without RF and 7 healthy individuals. Though it showed no
significant differences between RF-positive and RF-negative
patients, comparisons of gene expression patterns from all RA
patients and healthy controls identified a subset of discriminative
genes, amongst others, a significantly higher expression in RA
patients of the fatty-acid-Coenzyme A ligase (corresponding with
an ACSL, although specific isoform is undetermined) together
with others involved in immunoinflammatory responses, especially
those related to altered phagocytic functions [25].
As shown in fas-deficient mice and humans, autoimmunity can
be caused by the inability of the immune system to eliminate self-
reactive lymphocytes and hence maintaining autoreactive cells
that will recognise autoantibodies [5]. However, as shown in
complement deficiencies, increased apoptotic material and
altered clearance of apoptotic cells is found in patients with
SLE [2–4]. This suggest that what is found in rare individuals
with genetic deficiencies that develop SLE or SLE-like disease
may be found in the larger population of SLE patients as a
common end point pattern of unbalanced process of both
apoptosis and clearance of apoptotic material. The dysfunction of
apoptosis may be a direct consequence of alterations in proteins/
genes such as Fas, FasL, Bcl-2 and C1q [6]. On the other hand,
ACSL5 has previously been associated to both apoptosis and
surviving processes of tumors from different tissues [20,26],
thereby implying a role of ACSL5 in these pathways. In addition,
it has been described in SLE patients an augmented spontaneous
apoptosis of lymphocytes [5], which, in the same line with our
findings in patients, points to ACSL5 as a possible key molecule
regulating apoptosis in SLE, and hence exerting a role in SLE
pathogenesis.
Figure 4. Effect of ACSL5 silencing in the apoptosis induced in Jurkat T cells by PMA+Io activation. Jurkat T cells were electropororated
with either siRNA for ACSL5 (siACSL5) or unspecific control of siRNA (siRNA), and left for 18 h in culture media. Then both siACSL5 and siRNA Jurkat T
cells were cultured with or without PMA+Io for 24 h. A) ACSL5 expression at 24 h was determined in each type of culture as described in material and
methods. B) Percentage of apoptosis in siACSL5 or siRNA Jurkat T cells measured by cytometry as Annexin V positive and double Annexin V and PI
positive cells. C–I) Total RNA was extracted, cDNA synthesized and qRT-PCR implemented to determine mRNA expression. Results are given by means
of three independent experiments and the bars show the standard deviation. P-value has been calculated with the paired Student t test.
doi:10.1371/journal.pone.0028591.g004
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Our results from experiments in vitro confirmed a pro-apoptotic
role of ACSL5 in AICD occurring in lymphocyte cells, as this had
been previously demonstrated in hepatocytic cells, increasing TNF-
and TRAIL-mediated apoptosis [20]. Unlike this hypothesis, other
works have shown enhanced ACSL5 expression associated to the
development of colorectal cancer [21] and involved in surviving of
glioma cells under acidosis conditions [26], pointing to an anti-
apoptotic role. Taken together, ACSL5 may be able to play both pro-
and anti-apoptotic roles depending on tissue specificity, physiopa-
thology conditions and other factors, thus contributing to different
clinical manifestations appearing in complex diseases as SLE.
Apoptosis is a genetically controlled process initiated by two
principal pathways. The extrinsic pathway is activated by the
ligation of death receptors, and the intrinsic pathway emerges
from the mitochondria [5]. Lipids have long been associated to
apoptosis through lipid-peroxidation and mitochondrial perme-
ability transition [12], and, even though poorly understood, there
have been described marked changes in lipoproteins and
triglycerides in SLE patients [17]. Oxidized fatty acids found
augmented in sera from SLE patients include hydroxyls and
aldehydes that are linked to modification of lipids, proteins and
DNA; moreover, immunization with oxidatively modified auto-
antigens accelerate disease progress in MLR/lpr mice [27,28].
ACSLs are essential for lipid metabolism (synthesis and degrada-
tion) and acyl-modification of cellular components, mediated by its
enzymatic activation of fatty acids [7]. This, consequently, points
to these enzymes as possible regulators of these processes.
ACSL5 localizes in the mitochondria and microsomes [8,9],
from where it may execute its role in apoptosis, probably by
supplying fatty acids into the mitochondria, where they can
participate in oxidative reactions, increase ceramide synthesis and
affect the mitochondrial membrane potential [11,12,27–29].
Lipid-peroxidation is augmented in SLE and correlates with
disease activity [30,31], and has also been associated to exposition
of oxidized phosphatidylserine in the plasma membrane, associ-
ated with immunity and apoptosis due to recognition by
macrophages [32]. Overexpression of ACSL5 in SLE patients
may be an important key in predisposition and progression of
autoimmunity; pointing to the involvement of this enzyme in
supplying the material necessary for oxidative modification of
cellular and extracellular components in early stages of SLE and
SLE-like diseases, being ACSL5 directly associated with apoptosis
and thus leading to an augmented apoptosis and recognition of
these modified antigens by macrophages, which in the end could
activate lymphocytes and promote autoantibody production.
In conclusion, our findings point to ACSL5 as a key regulator of
AICD in lymphocytes, playing a pro-apoptotic role. We have found
that silencing ACSL5 decreases FAS, FASLG and TNF expression.
This supports the hypothesis that this enzyme is implicated in SLE
pathology not only by directly mediating the spontaneous apoptosis
occurring in SLE but also indirectly involved in presenting self-
antigens to immune cells and hence, promoting the pro-inflamma-
tory state for the predisposition and progression of autoimmune
diseases such as SLE. And probably by inducing TNF expression
among other pro-inflammatory genes. Future perspectives should
take into account the knowledge of molecular contribution of
ACSL5 in the apoptotic pathway. We therefore propose ACSL5 as
a diagnostic marker and potential therapeutic target for SLE.
Materials and Methods
Participants
Forty five Caucasian patients (39 female, 6 male), fulfilling the
American College of Rheumatology criteria for SLE [33], who
attended the out-patient clinic of the University Hospital Virgen
de las Nieves of Granada, Spain, were included (Table 1).
Exclusion criteria were less than 1 year of follow-up in our unit.
Current clinical assessment were made during a routinely visit and
other demographic and clinical data were obtained from the
medical records in a computer database. Disease activity and
accumulated organ damage were measured with the SLE Disease
Activity Index (SLEDAI) and the Systemic Lupus International
Collaborating Clinics/ACR Damage Index (SDI) respectively as
indicated in Table 1. Controls were healthy individuals attended
to the Blood Bank of Granada. Mean age of this group was similar
to the SLE group (P..05) but the % of females (49%) was rather
different to the SLE group (88%). So, we tested the effect on the
ACSL5 transcript levels of males and females as indicated in
Table 1.
Ethics Statment
All participants provided a written informed consent to
participate in this study, which was approved by the Institutional
Review Board of Hospital Virgen de las Nieves of Granada, Spain.
Cell cultures
Jurkat T cells (Clone E6-1, LGC/ATCCR) and peripheral
blood mononuclear cells (PBMCs) from anonymous donors in the
Blood Bank of Granada, Spain, were cultured in RPMI 1640
complete medium (PAA Laboratories, GmbH), supplemented with
10% (v/v) heat-inactivated fetal bovine serum, 2 mM (w/v)
glutamine, and 100 U/mL penicillin and 100 ug/mL streptomy-
cin (all from Gibco, Invitrogen. Carlsbad, CA), at 37uC / 5% CO2
atmosphere. Cells were maintained in an exponential growth
phase for all experiments. To study effect of Activating-Induced
Cell Death (AICD), 50 ng/mL Phorbol 12-Myristate 13-Acetate
(PMA) and 10 ng/mL Ionomycin (Io) (Sigma-Aldrich Inc.) were
added to the cultured cells for different-time experiments. Viable-
cell counting was carried out by Trypan Blue solution (Sigma-
Aldrich Inc.) staining.
ACSL5 transcript measurement
PBMCs were obtained from whole blood samples by Ficoll-
Hystopaque (Sigma-Aldrich Inc.) density centrifugation. Total
RNAs were isolated by using the RNeasy mini-kit (Qiagen,
Valencia, CA) and the mRNA purified by using the GenElute
mRNA Miniprep kit (Sigma-Aldrich Inc.) and stored at 280uC
until used.
cDNA was synthesized using a total of 200–500 ng mRNA of each
sample, reverse transcribed using the Superscript III reverse
transcription reagents (Invitrogen S.A., Invitrogene Ltd., UK) and
then subjected to RT-PCR. As a reference gene for normalization to
calculate the ACSL5 relative expression, the ubiquitin-conjugating
enzyme UBcH5B was used [34]. Amplifications of cDNAs were done
in triplicates using the sybr greenR Mastermix for real time-PCR
(Biorad Laboratories, Inc.) and 50 nmol of the following primer sets:
ACSL2 Forward 59-TTCGAAGAAGCCCTGAAAGA-39 and Re-
verse 59-AGAAATCAGCCACCACGTTC-39 (renamed as ACSL6,
ENST00000354273); ACSL4 Forward 59- TCCAAGTTTGGGAA-
GAAGGA-39 and Reverse 59-GGCAATGGTGTTCTTTGGTT-
39 (Ensemble ID, ENST00000354273), ACSL5 Forward: 59 – AA-
GGCATTGGTGCTGATAGG – 39 and Reverse: 59 – TCA-
GGTCTTCTGGGCTAGGA – 39 (Ensemble transcript ID
ENST00000357430); and UbcH5B as reference gene: Forward 59 –
CAATTCCGAAGAGAATCCACAAGGAATTG – 39 and Re-
verse: 59 – GTGTTCCAACAGGACCTGCTGAACAC – 39
(Ensemble transcript ID, ENST00000398733).
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PCR conditions were as follows: 1 cycle of 95uC for 3 min,
followed by 40 cycles of 95uC for 20 s, 62uC for 20s, and 72uC for
20 s. All assays were validated for linearity of amplification
efficiency. PCR efficiencies were calculated using a relative
standard curve derived from mixed cDNA of different samples
(a twofold dilution series with four measuring points). To ensure
the absence of amplification artefacts and primer dimmer
formation, end point PCR products were initially assessed on
ethidium bromide stained agarose gels that gave a single band of
the expected size for each assay. Negative controls containing no
template cDNA were run in each condition and gave no results.
The reactions were quantified when the PCR product of interest
was first detected (cycle threshold, CT). Calculations for relative
mRNA transcript levels were performed using the comparative
CT method_2_DDCT_ between cycle thresholds of different
reactions using Image Quant (Bio-Rad Laboratories Inc.).
ACSL5 from non-activated (N) and activated (A) PBMCs:
stimulation index (SI)
In a first step, we quantified ACSL5 mRNA levels from freshly
extracted PBMCs. The second type of measurement was done
after 24 h of in vitro stimulation by phorbol-myristate-acetate
(PMA) and ionomycin (Io). Finally, a parameter that we set up to
equilibrate differences due to undetermined factors between
measurements, was the stimulation index (SI), that is, the ratio
between activated and non-activated expression levels [23].
Apoptosis related mRNA expression
We quantified some relevant genes in the apoptotic pathway:
BCL-2 (ENSG00000171791), FAS (ENSG00000026103), FASLG
(ENSG00000117560), TRAIL (TNFSF10; ENSG00000121858),
TNF (ENSG00000232810) and CASP3 (ENSG00000164305).
Primers’ sequences are indicated in Table S1. cDNA was
synthesized using a total of 200–500 ng mRNA of each sample
and amplifications of cDNAs were done in triplicates. PCR
conditions were as follows: 1 cycle of 95uC for 3 min, followed by
45 cycles of 95uC for 20 s, 63uC for 20 s, and 72uC for 20 s.
Short interference RNA (siRNA)
To silence ACSL5 mRNA expression we electroporated Jurkat
cells with specific siRNA [35]. 300 nM of siACSL5 or the
transfection control (siRNA) (Dharmacon, Thermo Fisher Scien-
tific. Lafayette, CO) were introduced into Jurkat T cells with Cell
Line NucleofectorR Kit V Solution Box (Amaxa, Lonza Cologne
GmbH), following supplier instructions, and using the Nucleo-
fectorR II (Amaxa, Lonza Cologne GmbH) electroporator. After
transfection Jurkat T cells were cultured in complete medium for
18 h prior to further experiment.
Flow cytometry
We used Propidium Iodide (PI) (Sigma-Aldrich Inc.) staining to
detect hipodiploid cell fragments produced in PMA+Io-induced
apoptosis [36]. Cultured PBMCs or Jurkat T cells (activated and
non activated by PMA+Io for 24 h) were collected at 2, 6 and
24 h, washed twice with PBS-glucose at 2 mg/mL (VWR
International, LLC. Amresco Inc., OH) and fixed with cold
70% ethanol for 15 minutes at 4uC. Then we washed cells with
PBS-glucose and stained the activated and non activated cells with
final concentration of 100 ug/mL Propidium Iodide (PI) prior to
analysis with BD FACSCaliburTM flow cytometer (Becton,
Dickinson and Company).
Annexin V-FITC kit for apoptosis (Sigma-Aldrich Inc.) was
used for detection of phosphatidylserine in the outer plasma
membrane as a specific apoptotic marker [37], following
manufacturer’s instructions. Cells were cultured for 24 h in
presence or absence of PMA and ionomycin and collected at 2
and 24 h. Analyses of samples were carried out with the BD
FACSCaliburTM flow cytometer.
Statistics
Statistical analysis was performed using SPSS 15.0 for the
Windows software package (SPSS, Chicago, USA). We used the
nonparametric Mann-Whitney rank-sum test to test the signifi-
cance of the difference in the transcript levels of ACSL5(N),
ACSL5 (A) and ACSL5 (SI) between the healthy controls and SLE
patients; females and males from the control group; and
prednisone treated SLE patient group versus the untreated SLE
group. Relative ACSL5 mRNA levels are presented as medians
(range). To determine the effect on risk, we used simple logistic
regression analysis and results are expressed as logistic coefficient
(B), and odds ratios with the 95% confidence intervals. Receiver-
operating characteristic (ROC) curves (not shown) and the area
under the ROC curve (AUC) were used to assess the feasibility of
using peripheral blood mononuclear cell ACSL mRNA concen-
tration as diagnostic tools for detecting SLE. Paired Student T test
was performed for comparisons between control and PMA+Io-
activated and/or transfected Jurkat T cells. Errors bars are
presented as mean (standard deviation) from three independent
experiments. All analyses used a 2-sided level of significance of 5%
(P,0.05).
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